期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 22, 期 8, 页码 1373-1381出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2004.04.185
关键词
-
类别
资金
- NCI NIH HHS [U01 CA 70062, P01 CA 15396] Funding Source: Medline
Purpose To determine whether therapy with a DNA methyltransferase inhibitor is effective in achieving demethylation and gene re-expression in tumor DNA in patients. Methods Biopsy specimens were obtained from patients with Epstein-Barr virus-associated tumors, enrolled on a clinical trial of 5-azacitidine, within 72 hours of the conclusion of the last infusion of the first cycle of therapy, and compared to pretreatment specimens. Methylation-specific polymerase chain reaction, bisulfite genomic sequencing, and immunohistochemistry were used to assess demethylation and gene re-expression. Results Substantial degrees of demethylation were detected in all latent and lytic Epstein-Barr virus promoters examined. Immunohistochemistry suggested activation of a previously silent viral antigen expression in one instance. Conclusion Pharmacologic reversal of dense CpG methylation in tumor tissue can be achieved in patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据